Full Breakdown
Daraxonrasib Nearly Doubles Survival for Metastatic Pancreatic Cancer
6/7/2026, 12:43:36 AM
Breakthrough Phase 3 Trial Shows Near-Doubling of Survival
On May 31, 2026, Revolution Medicines reported results from a Phase 3 trial involving 500 patients with metastatic pancreatic cancer. Patients receiving the oral KRAS inhibitor daraxonrasib experienced a median overall survival of 13.2 months, compared with 6.7 months for those treated with standard chemotherapy. The trial indicated a 60 % reduction in the risk of death for the daraxonrasib arm.
KRAS-Driven Pancreatic Cancer and the Challenge of Targeting It
More than 90 % of pancreatic tumors harbor activating mutations in the KRAS gene, which locks the protein in a permanently active state and drives uncontrolled cell proliferation. Historically, KRAS has been labeled “undruggable” because its smooth surface lacks pockets for conventional small-molecule binding, limiting therapeutic options to non-specific chemotherapy that often yields modest benefit and significant toxicity.
Daraxonrasib’s Mechanism and Development
Daraxonrasib is administered orally once daily. Rather than binding KRAS directly, the compound attaches to cyclophilin A, a cellular chaperone that assists protein folding. The resulting complex engages active KRAS and blocks its signaling capacity, thereby halting the proliferative drive of KRAS-mutant cancer cells. Revolution Medicines is the developer of the drug.
Trial Outcomes and Safety Profile
The trial reported a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy, and a 60 % reduction in mortality risk. The most common adverse event was a prominent skin rash, affecting more than 86 % of participants. Additional frequent events included stomatitis, diarrhea, nausea and vomiting. Despite the high incidence of rash, discontinuation due to severe toxicity was lower than with chemotherapy, and patients reported improved quality of life and reduced pain.
Regulatory Outlook and Next Steps
Revolution Medicines announced the Phase 3 findings on May 31, 2026 and indicated that the data have been submitted for regulatory review in the United States and other jurisdictions. The company expects that the magnitude of the survival benefit may qualify daraxonrasib for expedited or priority review, potentially allowing market entry within months of approval. If approved, the drug would represent the first KRAS-targeted therapy for pancreatic cancer, redefining the standard of care for this historically lethal disease.
Safety Concerns and Criticism
The high prevalence of skin rash and other gastrointestinal toxicities has raised concerns about tolerability, especially in patients with limited performance status. Although discontinuation rates were lower than with chemotherapy, clinicians will need to monitor and manage rash, stomatitis, diarrhea, nausea and vomiting to maintain adherence. The safety profile underscores the importance of balancing efficacy gains with manageable side effects.
Verbatim Quotes
- “As a gastrointestinal oncologist and researcher specializing in early-phase clinical trials, I have seen the critical need for more effective therapies for patients with pancreatic cancer.” — Gastrointestinal oncologist and researcher (author)
- “I expect more clinical trials exploring combination therapies pairing KRAS inhibitors with other drugs to prevent tumors from developing resistance to treatment.” — Gastrointestinal oncologist and researcher (author)
- “Overall, daraxonrasib reduced the risk of death for metastatic pancreatic cancer patients by 60%.” — Revolution Medicines (Phase 3 trial presentation)
